Advisories
Health Canada has suspended authorization of Avastin (bevacizumab) for use in the treatment of metastatic breast cancer. Based on careful review, Health Canada has concluded that Avastin has not been shown to be safe and effective in this use. Hoffmann-La Roche Ltd. has been directed to remove this indication from Avastin's label, and the company has indicated it will comply. This decision does not affect Health Canada's authorization of Avastin for other types of cancer.
Hoffmann-La Roche Ltd has also updated the safety information in the Avastin product monograph regarding a higher incidence of new cases of ovarian failure observed in premenopausal women treated with Avastin (bevacizumab) in a phase III trial comparing mFOLFOX6 versus mFOLFOX6 plus Avastin as adjuvant treatment in patients with Stage II and III colon cancer. The company does not authorize the combination of Avastin and mFOLFOX6 as adjuvant treatment in patients with colon cancer.
Health Canada informs consumers and health care professionals that it is reviewing the dose-related heart risk of citalopram. Recent data suggest that high doses of citalopram (60 mg/day) can potentially lead to serious and possibly fatal arrhythmias by affecting the electrical activity of the heart. Once the review is complete, Health Canada will communicate its findings to consumers and health care professionals.
CooperVision has issued a voluntary recall of a limited number of encore100 toric and encore100 sphere contact lenses due to the presence of residue (silicone oil) on the lenses that may result in hazy vision, discomfort, severe eye pain or eye injuries requiring medical treatment. Consumers can check to see if their contact lenses are affected by this recall by entering the lot number at www.coopervision. com/international-recall/ca/en. Consumers are instructed to stop wearing the affected lenses immediately and to contact their eye care professional for advice.
Health Canada alerts consumers and health care professionals that the use of fluoroquinolone antibiotics in patients with myasthenia gravis may worsen symptoms such as breathing problems or muscle weakness. Health Canada has instructed Canadian manufacturers of fluoroquinolone antibiotics to update the labelling in the product monograph to include a warning on this risk. A complete list of fluoroquinolone antibiotics available in Canada is available at www.hc-sc.gc.ca/ ahc-asc/media/advisoriesavis/_2011/2011_147-eng. php#list.
Boehringer Ingelheim Ltd. and Sanofi-aventis Canada Inc. alert consumers and health care professionals of the risk of medication errors associated with brand name confusion involving Pradax (dabigatran etexilate) and Plavix (clopidogrel bisulfate). Since January 2011, there have been 5 cases of medication errors associated with the name confusion within Canada, including 1 case of non-serious bleeding after a medical procedure. Both companies are looking to find ways to mitigate the risk of medication errors related to the name confusion. For now, health care professionals are encouraged to include the generic name when referring to either medication. Spelling the name may be helpful for verbal prescriptions or medication reconciliation.
Eli Lilly Canada Inc. informs consumers and health care professionals of reports of increases in heart rate and blood pressure with Strattera (atomoxetine) in a recent analysis of company-sponsored clinical trials in 8417 pediatric patients. A similar effect has been observed in adult ADHD patients. Based on these data, the safety information in the product monograph has been updated with the following recommendations: 1) Strattera is contraindicated in patients with severe heart-related disorders; 2) use Strattera with caution in patients with QT prolongation and in those whose underlying medical condition could be worsened by increases in blood pressure or heart rate (e.g., patients with hypertension, cardiovascular or cerebrovascular disease); 3) monitor heart rate and blood pressure before treatment with Strattera, after a dose increase and periodically during treatment.
Eli Lilly Canada Inc. informs consumers and health care professionals that Xigris (drotrecogin alfa, activated) has been withdrawn worldwide, effective immediately.
Product Update
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C Incivek (telaprevir 375 mg tablets by Vertex Pharmaceuticals Canada Inc.), in combination with peginterferon alfa and ribavirin, is indicated for the treatment of genotype 1 chronic hepatitis C in adult patients with compensated liver disease, including cirrhosis, who are treatment-naïve or who have previously been treated with interferon-based treatment, including prior null responders, partial responders and relapsers. The combination offers a higher cure rate and shortens the duration of treatment.
Incivek interacts with a list of medications (check product monograph). Advise women of childbearing potential to use 2 forms of nonhormonal contraception; this also applies if the male partner is taking ribavirin. The dose is 750 mg 3 times daily, every 7 to 9 hours, with food, in combination with peginterferon alfa plus ribavirin for the first 12 weeks, then peginterferon and ribavirin is continued for an additional 12 or 36 weeks, depending on response history and viral response.
Onsolis (fentanyl citrate buccal soluble film by Valeant Canada) is indicated for the management of breakthrough pain in cancer patients $18 years who are already receiving, and who are tolerant of, opioid therapy for their persistent baseline cancer pain. CYP3A4 inhibitors may increase fentanyl exposure. The starting dose is 200 mcg for all patients with an interval of 4 hours between doses. The dose can be titrated by 200 mcg until adequate pain relief is achieved (maximum 1200 mg/ dose). Instruct patients to use a dry hand to press the pink side of the film to the inside of the wet cheek for 5 seconds until it sticks. Caution patients that chewing or swallowing the film may decrease the amount of fentanyl absorbed. Advise patients to wait at least 5 minutes after the application before drinking and until the film dissolves before eating. The film dissolves within 15 to 30 minutes after application.
Trajenta (linagliptin 5 mg tablets by Boehringer Ingelheim Ltd.), a DPP-4 inhibitor, is indicated in adults with type 2 diabetes mellitus to improve glycemic control in conjunction with diet and exercise in patients for whom metformin is inappropriate due to contraindication or intolerance. It is also indicated in combination with metformin, sulfonylurea or both in patients who have not achieved adequate glycemic control with these medications when combined with diet and exercise. The dose is 5 mg once daily. No dose adjustment is needed for patients with mild to moderate renal impairment; Trajenta is not recommended in patients with severe renal insufficiency, including those with ESRD. Hypoglycemia was frequently reported in patients on triple therapy.
Victrelis (boceprevir 200 mg capsules by Merck Canada Inc.) is indicated for the treatment of chronic hepatitis C genotype 1 infection in combination with peginterferon alfa and ribavirin in adults patients ($18 years) with compensated liver disease, including cirrhosis, who are previously untreated or who have failed previous therapy. Victrelis interacts with a list of drugs. Advise women of childbearing potential to use 2 forms of nonhormonal contraception; this also applies if the male partner is taking ribavirin. The dose is 800 mg every 7 to 9 hours with food starting on week 5 of peginterferon plus ribavirin. The total duration of therapy is between 28 and 44 weeks, depending on response history and viral response. Refer to the product monograph for details. Common side effects are fatigue, anemia, nausea, headache and dysgeusia. Monitor complete blood counts as neutropenia and thrombocytopenia may occur. Victrelis Triple is also available -a 2-week package that contains boceprevir, ribavirin and peginterferon alfa-2 b.
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New indications
Abilify (aripiprazole by Bristol-Myers Squibb) is now approved for the treatment of schizophrenia in adolescents 15 to 17 years.
Botox (botulinum toxin type A by Allergan Inc.) is now approved for the prophylaxis of headaches in adults with chronic migraine.
Lucentis (ranibizumab by Novartis Pharmaceuticals Canada Inc.) is now approved for the treatment of visual impairment due to macular edema secondary to retinal vein occlusion.
Sutent (sunitinib malate by Pfizer Canada Inc.) is now approved for the treatment of patients with unresectable locally advanced or metastatic, well-differentiated pancreatic neuroendocrine tumors whose disease is progressive.
Amlodipine/atorvastatin (tablets of all strengths) are now available from GenMed. This is a new alternative to Caduet. Valacyclovir 1000 mg caplets are now available from Apotex Inc. This is a new alternative to Valtrex.
Betahistine dihydrochloride
Atenolol 50 mg and 100 mg tablets from Sandoz Canada have been discontinued.
Butorphanol 10 mg/mL nasal spray and 25 mg tablets from Pharmascience Inc. have been discontinued.
Desocort lotion 0.05% from Galderma Canada has been discontinued. Desocort ointment 0.05% is available.
Minocin 50 mg capsules from Stiefel have been discontinued.
Rhotral 100 mg, 200 mg and 400 mg tablets from Sandoz Canada have been discontinued.
Vagifem 25 mcg vaginal tablets from Novo Nordisk have been discontinued. Vagifem 10 mcg is still available.
Intelence (etravirine by Janssen) is now available in 200 mg tablets; also available in 100 mg tablets.
Onglyza (saxagliptin by Bristol-Myers Squibb-Astra-Zeneca) is now available in 2.5 mg tablets for once-daily use in patients with moderate to severe renal impairment or in patients with ESRD requiring hemodialysis. Onglyza is also available in 5 mg tablets. n
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